LEGN Stock Analysis: Legend Biotech | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.717m USD | 12M Return: -42.5% | US52490G1022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.4M
Qual. Beats: 0
Rev. Trend: 98.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Legend Biotech Corporation (LEGN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications, operating primarily in the United States, China, and Europe. Headquartered in Somerset, New Jersey, and founded in 2014, the company focuses on advancing chimeric antigen receptor (CAR-T) therapies and related cell-based treatments.
Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a BCMA-directed CAR-T therapy for multiple myeloma (MM), developed and commercialized in partnership with Janssen Biotech under a collaboration and license agreement. The CAR-T class represents a personalized form of cell therapy in which a patients own T-cells are genetically engineered to target cancer, and Legends partnership with Janssen positions it within a competitive MM CAR-T landscape that also includes Bristol-Myers Squibbs ide-cel (Abecma).
Beyond cilta-cel, Legend maintains a broad pipeline of earlier-stage autologous CAR-T candidates targeting cancers such as acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, and lung cancers. The company is also developing allogeneic gamma delta CAR-T and CAR-NK therapies aimed at BCMA for MM, currently in investigator-initiated Phase 1 trials in China. Additionally, Legend holds a license agreement with Novartis Pharma AG to develop CAR-T therapies targeting delta-like ligand protein 3 (DLL3), an antigen associated with small cell lung cancer.
- Carvykti sales surge on expanding multiple myeloma market share
- Competition from Bristol Myers Abecma pressures market position
- Manufacturing scale-up drives Carvykti supply and revenue growth
| Net Income: -91.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 2.59 > 1.0 |
| NWC/Revenue: 64.80% < 20% (prev 123.5%; Δ -58.74% < -1%) |
| CFO/TA -0.10 > 3% & CFO -183.1m > Net Income -91.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.8m) vs 12m ago 5.25% < -2% |
| Gross Margin: 56.58% > 18% (prev 62.51%; Δ -5.94% > 0.5%) |
| Asset Turnover: 73.89% > 50% (prev 47.15%; Δ 26.74% > 0%) |
| Interest Coverage Ratio: -2.56 > 6 (EBIT TTM -43.1m / Interest Expense TTM 16.8m) |
| A: 0.47 (Total Current Assets 1.23b - Total Current Liabilities 403.6m) / Total Assets 1.75b |
| B: -1.13 (Retained Earnings -1.98b / Total Assets 1.75b) |
| C: -0.03 (EBIT TTM -43.1m / Avg Total Assets 1.72b) |
| D: 2.36 (Book Value of Equity 1.23b / Total Liabilities 521.3m) |
| Altman-Z'' = 1.71 = BBB |
| DSRI: 0.54 (Receivables 198.0m/229.0m, Revenue 1.27b/796.8m) |
| GMI: 1.10 (GM 62.51% / 56.58%) |
| AQI: 0.35 (AQ_t 0.04 / AQ_t-1 0.12) |
| SGI: 1.60 (Revenue 1.27b / 796.8m) |
| TATA: 0.05 (NI -91.6m - CFO -183.1m) / TA 1.75b) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of October 03, 2026, the stock is trading at USD 18.57 with a total of 2,528,902 shares traded. Over the past week, the price has changed by -2.83%, over one month by -15.17%, over three months by -37.91% and over the past year by -42.49%.
Current recommended Stop Loss: 16.30 (which is 12.2% or 2.5 ATR below the current price).
Legend Biotech has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LEGN.
- StrongBuy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 46.9 | 152.6% |
P/E Forward = 27.5482
P/S = 2.9233
P/B = 2.9183
Revenue TTM = 1.27b USD
EBIT TTM = -43.1m USD
EBITDA TTM = -7.24m USD
Long Term Debt = 110.0m USD (estimated: total debt 278.2m - short term 168.2m)
Short Term Debt = 168.2m USD (from shortTermDebt, last quarter)
Debt = 400.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 121.8m
Net Debt = -564.6m USD (calculated: Debt 400.0m - CCE 964.6m)
Enterprise Value = 3.15b USD (3.72b + Debt 400.0m - CCE 964.6m)
Interest Coverage Ratio = -2.56 (Ebit TTM -43.1m / Interest Expense TTM 16.8m)
EV/FCF = -12.33x (Enterprise Value 3.15b / FCF TTM -255.6m)
FCF Yield = -8.11% (FCF TTM -255.6m / Enterprise Value 3.15b)
FCF Margin = -20.10% (FCF TTM -255.6m / Revenue TTM 1.27b)
Net Margin = -7.21% (Net Income TTM -91.6m / Revenue TTM 1.27b)
Gross Margin = 56.58% ((Revenue TTM 1.27b - Cost of Revenue TTM 552.1m) / Revenue TTM)
Gross Margin QoQ = 64.54% (prev 42.35%)
Tobins Q-Ratio = 1.80 (Enterprise Value 3.15b / Total Assets 1.75b)
Interest Expense / Debt = 4.21% (Interest Expense 16.8m / Debt 400.0m)
Taxrate = 40.18% (22.3m / 55.5m)
NOPAT = -25.8m (EBIT -43.1m * (1 - 40.18%)) [loss with tax shield]
Current Ratio = 3.04 (Total Current Assets 1.23b / Total Current Liabilities 403.6m)
Debt / Equity = 0.33 (Debt 400.0m / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 77.94 (negative EBITDA) (Net Debt -564.6m / EBITDA -7.24m)
Debt / FCF = 2.21 (negative FCF - burning cash) (Net Debt -564.6m / FCF TTM -255.6m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.32% (Net Income -91.6m / Total Assets 1.75b)
RoE = -8.70% (Net Income TTM -91.6m / Total Stockholder Equity 1.05b)
RoCE = -3.71% (EBIT -43.1m / Capital Employed (Equity 1.05b + L.T.Debt 110.0m))
RoIC = -1.78% (negative operating profit) (NOPAT -25.8m / Invested Capital 1.45b)
WACC = 9.20% (E(3.72b)/V(4.12b) * Re(9.92%) + D(400.0m)/V(4.12b) * Rd(4.21%) * (1-Tc(0.40)))
Discount Rate = 9.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.26 | Cagr: 2.83%
[DCF] Fair Price = unknown (Cash Flow -255.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 98.92 | Revenue CAGR: 84.22% | SUE: 1.41 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.01 | Chg30d=N/A | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+99.4% | GrowthRev=+39.3%
EPS next Year (2027-12-31): EPS=0.68 | Chg30d=-22.73% | Revisions=-25% | GrowthEPS=+8291.9% | GrowthRev=+25.3%
[Analyst] Revisions Ratio: -50% (up=0, down=3)